BIONATURIS (BIOORGANIC R.) D2015-JUNIO

Trading sesion


15/06/2015 Close

0.0100

Last price


0.05 mill. €

Capitalisation

0.00

Dif.(%)


0.00

% Year 2015

Excluded 16/06/2015

Last Trade

Last

0.0100

Ref.

0.0100

Dif.(%)

0.00

Volume (Shares)

66,987

Turnover (€x1000)

0.67

Security

Security name

BIONATURIS (BIOORGANIC R.) D2015-JUNIO

Ticker

86026

ISIN

ES0684980917

NIF

A-11811163

Capital Admitted

-

Shares Admitted

4.633.036

Nominal

-

Trading

Continuo

Liquidity Provider

GVC GAESCO BEKA, S.V., S.A.

Registered Advisor

DCM ASESORES Dirección y Consultoría de Mercados, S.L.

Auditor

PAEZ & SERRANO AUDITORIES, S.L.U.

Address

AV DESARROLLO TECNOLOGICO 11, JEREZ DE LA FRONTERA

Contact

ir@bionaturis.com

Historical Summary

 2015 until 15/06

Capital Admitted (thousands of euros)

n/a

Shares (x 1,000)

4,633

Period Close Price (euros)

0.0100

Period Last Price (euros)

0.0100

Period High Price (euros)

0.0300

Period Low Price (euros)

0.0100

Capitalisation (thousands of euros)

46

Volume (thousands of shares)

366

Turnover (thousands of euros)

5

Company Profile

Bionaturis -established in Cadiz in 2005- is a biopharmaceutical company developing and producing biomedical products for the pharmaceutical and veterinarian sectors. Bionaturis specializes in the prevention and treatment of niche diseases, such as orphan diseases.

As value proposition Bionaturis has chosen Nature as an optimized source for the production of biopharmaceuticals, substituting the traditional industrial cumbersome steel reactors for single use, disposable and naturally occurring individual reactors: FLYLIFEÒ.  FLYLIFEÒ makes use of natural resources to achieve and indeed surpass the productive capacity of traditional industry standards but utilizing up to ten-fold less space and fifteen-fold less investment.  Amongst others, in niche markets where currently there is no solution, these competitive advantages provide a profitable solution and gives renewed hope to millions of worldwide patients. 

Its mission is to position itself as leader within the field of new platforms for production of biopharmaceuticals for veterinary and human use, and convert itself into a worldwide reference entity for the development of orphan drugs.

To complete its mission Bionaturis has chosen a mixed business model which combines short-term income through R+D services and production for third parties (BNT-CDMO), this in combination with co-development of biopharmaceuticals, which generates incomes through licensing royalties and the completion of milestones in the medium and long term (BNT-PRODUCTS).

 Year on year Bionaturis has increased the portfolio of international patents, either developed internally or acquired through license.  

Relevant Facts and Notices

Financial Reports

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Copyright © Bolsas y Mercados Españoles 2016. All rights reserved. Disclaimer // Legal Disclaimer // Suppliers payment period